Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group
Sponsor study identifier
observational
300
4 countries
6
Study Start
August 25, 2021
Actual (reported)Primary Completion
August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 25, 2021
Actual (reported)January 5, 2022
Actual (reported)February 9, 2022
Actual (reported)August 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
2-year overall survival (OS)
OS measured from the date of diagnosis to last follow-up or to death from any cause.
2 years
2-year progression-free survival (PFS)
PFS calculated from the date of diagnosis to the time of progression, relapse, or death.
2 years
Incidence of relapse (IR)
5 years
Non-relapse mortality (NRM)
5 years
5-year overall survival (OS)
5 years
5-year progression-free survival (PFS)
5 years
Unselected cohort of adults with HIV-lymphoma
Red Cross Hospital Munich
Munich, Select One Option, 80634, Germany
University Hospital Cologne
Cologne, 50937, Germany
Marcus Hentrich, MD
Rotkreuzklinikum München
First Submitted
January 5, 2022
First Posted
February 9, 2022
Study Start
August 25, 2021
Actual (reported)Primary Completion
August 31, 2024
Estimated (date passed)Contact the study team to confirm eligibility.
Amsterdam University Medical Centers
Amsterdam, Netherlands
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
University Hospital of Wales
Cardiff, United Kingdom
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 6, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: